AIMT - Did the FDA Just Signal Smooth Sailing Ahead For Aimmune Therapeutics?
Aimmune Therapeutics (NASDAQ: AIMT) has for a long time been desensitizing people with severe peanut allergies to their nemesis with AR101. In a nutshell, U.S. regulators recently gave the candidate, to be named Palforzia, a big push toward marketing approval and blockbuster sales.
This does not mean peanut butter and jelly sandwiches are returning to our nation's schools, but it has made this biotech stock significantly more attractive. Here's what a complicated briefing document from the Food and Drug Administration (FDA) means for Aimmunne shareholders, and what it doesn't mean.
Image source: Getty Images.